DCM
TYRA icon

Defilade Capital Management’s Tyra Biosciences TYRA Stock Holding History

Defilade Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Buy
+376,870
New +$12.5M 1.61% 24

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Defilade Capital Management's TYRA Position: Q2 2026 in Review

Defilade Capital Management opened a new position in Tyra Biosciences (TYRA) in Q2 2026: 376,870 shares worth $12M. The stake represents 1.61% of the portfolio and ranks #24 among its holdings.

170 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Defilade Capital Management held 376,870 shares of Tyra Biosciences worth $12M as of Q2 2026.
  • Tyra Biosciences was a new Defilade Capital Management position in Q2 2026.
  • Tyra Biosciences made up 1.61% of Defilade Capital Management's portfolio in Q2 2026, its #24 holding.
  • 170 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.